Share Price | Aptus Pharma Ltd Stock Analysis & Recommendation

Q: Why is Aptus Pharma Ltd falling/rising?

As of 04-Mar, Aptus Pharma Ltd's stock price is currently at 261.25, reflecting a decline of 5.3 points or 1.99%. The stock has been underperforming, having lost 3.93% over the last two days, which indicates a consecutive fall. Additionally, the stock's performance today has underperformed its sector by 0.9%. In terms of recent trading activity, the stock has shown erratic trading patterns, not trading on one day out of the last 20 days, and it has traded within a narrow range of Rs 0.1. Although there has been a rise in investor participation, with a delivery volume increase of 66.67% on February 26 compared to the 5-day average, this has not translated into positive price movement. Moreover, while the stock's price is higher than the 20-day, 50-day, 100-day, and 200-day moving averages, it is lower than the 5-day moving average, suggesting a short-term weakness. Overall, these factors contribute to the stock's current decline.

Technical Trend Update: Aptus Pharma witnessed a change in Technical Grade on 05 Mar 2026. Click here to discover latest technical change!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.0 k (-70.59%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

72.89%

Why is Aptus Pharma Ltd falling/rising?

05-Mar-2026

As of 04-Mar, Aptus Pharma Ltd's stock price is at 261.25, down 1.99% and has underperformed its sector by 0.9%. Despite increased investor participation, the stock shows short-term weakness and has declined over the last two days.

View full answer

Which are the latest news on Aptus Pharma?

05-Mar-2026

No latest news for Aptus Pharma found.

Compare Aptus Pharma with Similar Stocks

Brooks Lab.Auro Labs.Oxygenta Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 179 Cr (Micro Cap)

P/E

62.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.28

Return on Equity

13.64%

Price to Book

8.26

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

63.97%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Aptus Pharma for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

No Recent News for the Company

Announcements

Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015: Business Expansion

26-Feb-2026 | Source : BSE

Intimation under Regulation 30 of SEBI (LODR) Regulations 2015: Business Expansion

Intimation Of Award Received: Recognition As Fastest Growing Ethical Pharma Company

24-Feb-2026 | Source : BSE

Intimation of Award Received: Recognition as Fastest Growing Ethical Pharma Company

Announcement under Regulation 30 (LODR)-Investor Presentation

07-Feb-2026 | Source : BSE

Intimation of Investor Presentation under Regulation 30 of SEBI (LODR) Regulations 2015

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

2.91

Debt to EBITDA (avg)

1.71

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.82

Tax Ratio

27.80%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

28.87%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

8.42

EV to EBIT

39.34

EV to EBITDA

37.19

EV to Capital Employed

11.36

EV to Sales

7.19

PEG Ratio

Dividend Yield

ROCE (Latest)

28.87%

ROE (Latest)

13.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

RSI

Bearish

Bollinger Bands

Mildly Bullish

KST

Dow Theory

Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Kapilbhai Hasmukhbhai Chandarana (11.3%)

Highest Public shareholder

Saint Capital Fund (4.29%)

Individual Investors Holdings

22.97%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Aptus Pharma"
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Aptus Pharma"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Aptus Pharma"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "alert": "No Annual Results declared by Aptus Pharma"
  }
]

Company CV

About Aptus Pharma Ltd

Aptus Pharma Ltd

Micro Cap

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available